American Association for Cancer Research

Changes in oncology treatments may lead to changes in clinical trial design: An overview of a basket trial in progress

Thursday, June 1, 2017

As technology and science have evolved over the last several years, new treatment modalities for cancer have emerged. These new treatment options have presented a challenge for researchers. How do we translate new scientific advancements to patient populations rapidly and effectively, especially in oncology? Arguments that the drug development process is “broken” have stimulated improvements in clinical trial designs.1 One category of clinical trial design that has emerged as a result is a master protocol. Several designs fall under the master protocol category.

[Read More]

Placon Therapeutics launches, BTP-114 IND accepted by FDA

Wednesday, March 23, 2016

Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BTP-114, for which the FDA has accepted an Investigational New Drug (IND) application to begin clinical evaluation in cancer patients. Placon was spun out from Blend Therapeutics (now Tarveda Therapeutics) to distinctly focus on a pipeline of innovative platinum-based assets.

[Read More]

Andrew S. Kraft named director of University of Arizona Cancer Center

Monday, June 9, 2014

Dr. Andrew S. Kraft, a prostate cancer physician-scientist and cancer center administrator, has been named the Sydney E. Salmon endowed chair and director of the University of Arizona Cancer Center and associate vice president for oncology programs for the UA Health Sciences Center. In addition, Kraft joins the University as a tenured professor of medicine in the department of Medicine’s Division of Hematology/Oncology and senior associate dean for translational research in the College of Medicine.

[Read More]